Topic:

Infectious Diseases

Latest Headlines

Latest Headlines

Study: Serum Institute's powdered measles vaccine inferior to traditional jab

In December, Serum Institute of India reported victory in a Phase I trial of its powdered measles vaccine. But it may have to go back to the drawing board as results from a noninferiority trial reported Thursday showed that the powdered candidate was not as effective as the traditional injected vaccine.

Merck takes its Ebola vaccine to Phase III in Sierra Leone

In the latest development in the race for an Ebola vaccine, Merck and partner NewLink have taken their candidate to late-stage trials in Sierra Leone, the companies announced Tuesday.

Sanofi 'flipping the model' for high-stakes dengue rollout

After the company's largest investment ever in the development of a vaccine, Sanofi Pasteur's dengue vaccine launch is ready for this year, and it'll be closely watched as the group introduces the jab in a manner reversed from traditional launches.

GlaxoSmithKline and Merck Ebola vaccines succeed in Phase II Liberian trials

Two Ebola vaccines, one developed by the NIH and GlaxoSmithKline and the other by Merck and NewLink, have sailed through Liberian trials and, based on the results, may now advance to Phase III trials.

Sanofi, Merck win EMA nod for Gardasil 9

Merck's new-and-improved Gardasil is making headway in Europe with the word late last week that the European Medicines Agency has recommended the jab against 9 types of human papillomavirus and will send its blessing to the European Commission.

Chinese Ebola vaccine based on current strain looks safe in PhI

Results from the Phase I trial of yet another experimental Ebola vaccine are in, but unlike other vaccines in the field, this one is based on the virus strain that caused the 2014 epidemic, and not an older one. The vaccine, developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology, is called a recombinant adenovirus type-5 vaccine.

GSK, U.K. 'hopeful' they can strike a Bexsero price deal soon

It's been 7 months since price negotiations over meningitis B vaccine Bexsero began between Novartis and the U.K. government. And as far as new owner GlaxoSmithKline is concerned, that's long enough.

GSK to test Ebola jab with booster from Emergent BioSolutions

GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.

England to provide GSK MenW vaccine to 3 million teens

England has decided to offer meningitis W vaccination to three million teens after a steep rise in cases--and local vaccine giant GlaxoSmithKline will be reaping the benefits.

J&J, Merck to advance Ebola vaccines in Africa, but their fate rests in WHO's hands

Johnson & Johnson is ready to start trialing its Ebola vaccine in Africa, where Merck and NewLink are preparing to take theirs into Phase III. GlaxoSmithKline is also testing its jab there. But while thousands of healthcare workers have volunteered to participate in Ebola vaccine trials, the decision to mass-vaccinate against the disease is still up in the air.